<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03382665</url>
  </required_header>
  <id_info>
    <org_study_id>BMETEU.CR.EU79.10</org_study_id>
    <nct_id>NCT03382665</nct_id>
  </id_info>
  <brief_title>Post-market Surveillance Study With the HYPERION Hip Endoprosthesis System in Defect Reconstruction</brief_title>
  <official_title>Prospective, Multi - Centre Clinical Evaluation of the Performance and Safety of the HYPERION Hip Endoprosthesis System in Defect Reconstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zimmer Biomet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zimmer Biomet</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a multi-center, prospective, non-controlled, consecutive cohort post market&#xD;
      surveillance study. The objective of this study is to obtain survival and clinical outcome&#xD;
      data on the Hyperion® system in primary and revision total hip arthroplasty.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multi-center, prospective, non-controlled, consecutive cohort post market surveillance&#xD;
      study will serve the purpose of confirming long-term safety and performance of the Hyperion®&#xD;
      system. The performance of the Hyperion® THA System will be evaluated using standard scoring&#xD;
      systems (Merle d'Aubigné Score, HOOS Score). Safety will be evaluated by adverse event&#xD;
      reporting.&#xD;
&#xD;
      The study will be performed at 6 sites, enrolling in total 70 patients. Follow-up visits are&#xD;
      planned after 3 to 6 month, 1, 2 and 5 years. The scores will be filled in pre-operatively&#xD;
      and post-operatively until 5 years. In order to obtain mid- to long-term patient satisfaction&#xD;
      data the patient questionnaire will be send to the patient at 7 and 10 years, additionally.&#xD;
      Xrays will be done pre-operatively, immediate post-operatively and at each of the Follow-up&#xD;
      visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    CE mark will not be renewed, PMCF data no longer required&#xD;
  </why_stopped>
  <start_date type="Actual">January 2010</start_date>
  <completion_date type="Actual">March 2018</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pain and Walking Ability Determined by a Merle d' Aubigné Score Increase of &gt;4 Points.</measure>
    <time_frame>baseline/Pre-op and 2 years (+/- 2 months)</time_frame>
    <description>Pain and walking ability determined by a Merle d' Aubigné Score (MdA) increase of &gt;4 points compared to the pre-operative score points.&#xD;
The patients were evaluated by the Merle d'Aubigné hip score, which evaluates pain, gait and mobility, on a scale of 1 to 6 for each item, where 1 indicates the worst and 6, the best state of the patient. The value of each item is summed to a total score. The total minimum score reached is 3, and the maximum is 18. Higher scores mean a better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Implant Survival Measured by the Number of Revisions.</measure>
    <time_frame>2 years (+/- 2 month)</time_frame>
    <description>Implant survival is measured by the number of revisions and analysed by the Kaplan Meier method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>WOMAC Score Value Decrease at 2-years in Min. 25 Points Compared to the Pre-operative WOMAC Score Value</measure>
    <time_frame>baseline/Pre-op and 2 years (+/- 2 months)</time_frame>
    <description>at 2-years post op, WOMAC score (Western Ontario and McMaster Universities Arthritis Index) has to be at least 25 points lower compared to preop values&#xD;
Scale: min 0-Max 100; Higher values mean worse outcome</description>
  </primary_outcome>
  <enrollment type="Actual">70</enrollment>
  <condition>Osteoarthritis</condition>
  <condition>Avascular Necrosis</condition>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Functional Deformities</condition>
  <condition>Pseudoarthrosis</condition>
  <condition>Revision of Endoprosthesis-treated Hips</condition>
  <condition>Fracture, Proximal Humeral</condition>
  <condition>Provision of Non-endoprosthetic Previous Operations of the Hip Joint (e.g., Transposition Osteotomies)</condition>
  <condition>Femur Fracture</condition>
  <condition>Pseudarthrosis</condition>
  <condition>Trochanteric Fractures</condition>
  <condition>Bridging of Large Bone Defects</condition>
  <condition>Revisions</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Because of the studiesindications it is assumed that patients have a relatively high (&gt; 60&#xD;
        Jahre) age at the time of their operations. Therefore a higher letality and a higher&#xD;
        drop-out-rate is expected compared to study populations of primary hip replacement. To&#xD;
        reach the necessery power for this clinical study at least 70 patients should be recruited.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient age at least 18 years&#xD;
&#xD;
          -  Fully conscious and capable patients&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Stationary treatment&#xD;
&#xD;
          -  Merle d'Aubigné &lt; 12 Points, WOMAC Score &gt; 25 Points&#xD;
&#xD;
          -  Patients with at least one of the following indications:&#xD;
&#xD;
        Indications for primary hip replacement:&#xD;
&#xD;
          -  Non-inflammatory diseases of the joints such as osteoarthritis and avascular necrosis&#xD;
             (head necrosis)&#xD;
&#xD;
          -  Rheumatoid arthritis&#xD;
&#xD;
          -  Functional deformities&#xD;
&#xD;
          -  Provision of non-endoprosthetic previous operations of the hip joint (e.g.,&#xD;
             transposition osteotomies)&#xD;
&#xD;
          -  Treatment of pseudarthrosis, femoral neck and trochanter fractures, as well as&#xD;
             fractures of the proximal femur affecting the head, which can not be treated by other&#xD;
             techniques&#xD;
&#xD;
        Revision THA:&#xD;
&#xD;
          -  Revision of endoprosthesis-treated hips as a result of septic or aseptic loosening,&#xD;
             sub- and periprosthetic fractures or material failure (eg fracture of the prosthesis)&#xD;
&#xD;
          -  Bridging of large bone defects (precondition: suitable proximal bone situation for a&#xD;
             stable anchorage), i.e. for tumors&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Infections&#xD;
&#xD;
          -  Patients under 18 years&#xD;
&#xD;
          -  Pregnant or breastfeeding patients&#xD;
&#xD;
          -  Known alcohol abuse (at least 20 g alcohol per day for women and at least 40 g per day&#xD;
             for men) or drug abuse&#xD;
&#xD;
          -  Legal incapacity or restricted capacity&#xD;
&#xD;
          -  Participation in another clinical trial within the last 30 days or planned&#xD;
             participation in another clinical trial within the next 3 months&#xD;
&#xD;
          -  Patients who are unable to attend to follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paola Vivoda</last_name>
    <role>Study Director</role>
    <affiliation>Zimmer Biomet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helios Klinik Hildesheim</name>
      <address>
        <city>Hildesheim</city>
        <zip>31135</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Osnabrück GmbH</name>
      <address>
        <city>Osnabrück</city>
        <zip>49076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Orthopädische Klinik Lindenlohe</name>
      <address>
        <city>Schwandorf In Bayern</city>
        <zip>92421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>December 19, 2017</study_first_submitted>
  <study_first_submitted_qc>December 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2017</study_first_posted>
  <results_first_submitted>April 30, 2020</results_first_submitted>
  <results_first_submitted_qc>August 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 21, 2020</results_first_posted>
  <last_update_submitted>August 10, 2020</last_update_submitted>
  <last_update_submitted_qc>August 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Revision total hip arthroplasty</keyword>
  <keyword>Medical Device</keyword>
  <keyword>Post Market Surveillance Study</keyword>
  <keyword>Primary total hip arthroplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Necrosis</mesh_term>
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Femoral Fractures</mesh_term>
    <mesh_term>Pseudarthrosis</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
    <mesh_term>Shoulder Fractures</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 4, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT03382665/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Patients, Suffering From Severe Hip Pain and Disability</title>
          <description>Patients in need of a total hip arthroplasty</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Actual Enrollment</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>5 Year Follow up</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Patients, Suffering From Severe Hip Pain and Disability</title>
          <description>Patients in need of a total hip arthroplasty</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="61"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Data available for 57 Patients</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.1" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <population>BMI available for 56 patients</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.9" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Operative Side</title>
          <population>Data on operative side available for 59 patients</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>LEFT</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>RIGHT</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain and Walking Ability Determined by a Merle d' Aubigné Score Increase of &gt;4 Points.</title>
        <description>Pain and walking ability determined by a Merle d' Aubigné Score (MdA) increase of &gt;4 points compared to the pre-operative score points.&#xD;
The patients were evaluated by the Merle d'Aubigné hip score, which evaluates pain, gait and mobility, on a scale of 1 to 6 for each item, where 1 indicates the worst and 6, the best state of the patient. The value of each item is summed to a total score. The total minimum score reached is 3, and the maximum is 18. Higher scores mean a better outcome.</description>
        <time_frame>baseline/Pre-op and 2 years (+/- 2 months)</time_frame>
        <population>MdA score not available for all participants</population>
        <group_list>
          <group group_id="O1">
            <title>Patients, Suffering From Severe Hip Pain and Disability</title>
            <description>Preop MdA scores</description>
          </group>
          <group group_id="O2">
            <title>Patients, Suffering From Severe Hip Pain and Disability 1</title>
            <description>2-year MdA scores</description>
          </group>
        </group_list>
        <measure>
          <title>Pain and Walking Ability Determined by a Merle d' Aubigné Score Increase of &gt;4 Points.</title>
          <description>Pain and walking ability determined by a Merle d' Aubigné Score (MdA) increase of &gt;4 points compared to the pre-operative score points.&#xD;
The patients were evaluated by the Merle d'Aubigné hip score, which evaluates pain, gait and mobility, on a scale of 1 to 6 for each item, where 1 indicates the worst and 6, the best state of the patient. The value of each item is summed to a total score. The total minimum score reached is 3, and the maximum is 18. Higher scores mean a better outcome.</description>
          <population>MdA score not available for all participants</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="3.7"/>
                    <measurement group_id="O2" value="13.8" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Implant Survival Measured by the Number of Revisions.</title>
        <description>Implant survival is measured by the number of revisions and analysed by the Kaplan Meier method.</description>
        <time_frame>2 years (+/- 2 month)</time_frame>
        <population>number of revisions at 2 years</population>
        <group_list>
          <group group_id="O1">
            <title>Patients, Suffering From Severe Hip Pain and Disability</title>
            <description>Patients in need of a total hip arthroplasty</description>
          </group>
        </group_list>
        <measure>
          <title>Implant Survival Measured by the Number of Revisions.</title>
          <description>Implant survival is measured by the number of revisions and analysed by the Kaplan Meier method.</description>
          <population>number of revisions at 2 years</population>
          <units>implants</units>
          <param>Count of Units</param>
          <units_analyzed>implants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>WOMAC Score Value Decrease at 2-years in Min. 25 Points Compared to the Pre-operative WOMAC Score Value</title>
        <description>at 2-years post op, WOMAC score (Western Ontario and McMaster Universities Arthritis Index) has to be at least 25 points lower compared to preop values&#xD;
Scale: min 0-Max 100; Higher values mean worse outcome</description>
        <time_frame>baseline/Pre-op and 2 years (+/- 2 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients, Suffering From Severe Hip Pain and Disability 1</title>
            <description>Preop Total WOMAC scores</description>
          </group>
          <group group_id="O2">
            <title>Patients, Suffering From Severe Hip Pain and Disability</title>
            <description>2-year Total WOMAC scores</description>
          </group>
        </group_list>
        <measure>
          <title>WOMAC Score Value Decrease at 2-years in Min. 25 Points Compared to the Pre-operative WOMAC Score Value</title>
          <description>at 2-years post op, WOMAC score (Western Ontario and McMaster Universities Arthritis Index) has to be at least 25 points lower compared to preop values&#xD;
Scale: min 0-Max 100; Higher values mean worse outcome</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.8" spread="22.4"/>
                    <measurement group_id="O2" value="27.5" spread="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for the entire duration of the study, from first surgery to last follow up at 5 years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Patients, Suffering From Severe Hip Pain and Disability</title>
          <description>Patients in need of a total hip arthroplasty</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General SAE</sub_title>
                <description>Serious Adverse Events were monitored/assessed without regard to the specific Adverse Event Term</description>
                <counts group_id="E1" events="38" subjects_affected="38" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General AE</sub_title>
                <description>Adverse Events were monitored/assessed without regard to the specific Adverse Event Term</description>
                <counts group_id="E1" events="33" subjects_affected="33" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination of the study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Fabrizio Lucchini, Clinical Jr.Project Lead</name_or_title>
      <organization>Zimmer Biomet</organization>
      <phone>0041798575924</phone>
      <email>Fabrizio.Lucchini@zimmerbiomet.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

